Sagimet Biosciences Inc Series A (SGMT) Stock Price, Quote & News

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

Iightning Dec. 5 at 6:28 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.46 Return: +28.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:16 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.46 Return: +28.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

shibadad Dec. 4 at 7:43 PM

$SGMT The FDA is considering moving to single pivotal trials. This could speed up acne commercialization by 8-12 months. Probably won't change much for the MASH timeline. https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

Iightning Dec. 4 at 7:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $5C Entry: 1.60 Exit: 3.18 Return: +98.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

John___wick44 Dec. 3 at 2:46 PM

$SGMT lets get this to the 3’s over next few months to load back up. this is a rinse amd repeat stock now.

0 · Reply

Iightning Dec. 3 at 10:47 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.93 Return: +39.60% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

John___wick44 Dec. 3 at 1:14 AM

$SGMT tax loss selling is starting to kick in as well. interesting to see how low it goes.. under 4 i will add back in

0 · Reply

shibadad Dec. 2 at 9:04 PM

$SGMT Despite the technicals, the fundamentals and data are still there. $125M in cash and another $125M (at least) due from Asceltis in the form of milestone payments and royalties for acne. Cash value is essentially $7.25/share. Non-China acne and MASH are free options at this point. Each could be worth $1B by themselves.

2 · Reply

rational1 Dec. 2 at 8:47 PM

$SGMT Silver lining - gap filled from 9/17

0 · Reply

FishStacker Dec. 2 at 8:23 PM

$SGMT I guess they didn’t impress anyone at the Evercore conference today ? What’s going on with this stock? Up and down like a yo yo.

0 · Reply

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 18, 2025, 5:48 AM EST - 16 days ago

Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts

Nov 10, 2025, 7:00 AM EST - 24 days ago

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Oct 24, 2025, 7:00 AM EDT - 5 weeks ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Oct 14, 2025, 6:00 AM EDT - 7 weeks ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 7, 2025, 9:30 AM EDT - 2 months ago

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts

Oct 7, 2025, 7:00 AM EDT - 2 months ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 10, 2025, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 7, 2025, 10:05 PM EDT - 3 months ago

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 29, 2025, 11:19 AM EDT - 3 months ago

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 13, 2025, 7:30 AM EDT - 4 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 9, 2025, 7:00 AM EDT - 6 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 4, 2025, 1:45 PM EDT - 6 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 5:00 AM EDT - 6 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

May 22, 2025, 8:00 AM EDT - 7 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 8, 2025, 6:00 AM EDT - 7 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 9 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 9 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 7, 2025, 4:27 PM EST - 9 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Nov 14, 2024, 3:56 PM EST - 1 year ago

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 18, 2024, 3:10 PM EDT - 1 year ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Jan 25, 2024, 8:58 PM EST - 2 years ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 24, 2024, 1:55 PM EST - 2 years ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 23, 2024, 5:45 PM EST - 2 years ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 22, 2024, 11:10 PM EST - 2 years ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 2 years ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Dec 4, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Nov 28, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Iightning Dec. 5 at 6:28 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.46 Return: +28.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:16 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.46 Return: +28.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

shibadad Dec. 4 at 7:43 PM

0 · Reply

Iightning Dec. 4 at 7:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $5C Entry: 1.60 Exit: 3.18 Return: +98.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

John___wick44 Dec. 3 at 2:46 PM

$SGMT lets get this to the 3’s over next few months to load back up. this is a rinse amd repeat stock now.

0 · Reply

Iightning Dec. 3 at 10:47 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SGMT Contract: Dec 19 $2.5C Entry: 4.25 Exit: 5.93 Return: +39.60% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

John___wick44 Dec. 3 at 1:14 AM

$SGMT tax loss selling is starting to kick in as well. interesting to see how low it goes.. under 4 i will add back in

0 · Reply

shibadad Dec. 2 at 9:04 PM

2 · Reply

rational1 Dec. 2 at 8:47 PM

$SGMT Silver lining - gap filled from 9/17

0 · Reply

FishStacker Dec. 2 at 8:23 PM

$SGMT I guess they didn’t impress anyone at the Evercore conference today ? What’s going on with this stock? Up and down like a yo yo.

0 · Reply

John___wick44 Dec. 2 at 6:25 PM

$SGMT game over. they are just too far away so too much uncertainty on how much money is needed. great company just need to revisit. they are not going to sell. getting there ip all taken care of. good luck all

1 · Reply

John___wick44 Dec. 2 at 5:52 PM

$SGMT send it down to 4. lets roll.

0 · Reply

shibadad Dec. 2 at 4:31 PM

$SGMT All biotechs getting whacked because of this... WASHINGTON — Top drug regulator Richard Pazdur filed papers to retire from the Food and Drug Administration at the end of this month, according to two agency sources familiar with the matter. Pazdur informed leaders at the FDA's drug center of his intention to leave the agency at a meeting on Tuesday.

2 · Reply

John___wick44 Dec. 2 at 2:42 PM

$SGMT take it to 4 scam mm lets go

0 · Reply

Iightning Dec. 2 at 2:24 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $SGMT **Contract:** Dec 19 $7.5C **Entry:** 0.29 **Exit:** 0.53 **Return:** **+83.19% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

John___wick44 Dec. 1 at 3:14 PM

$SGMT back to 4 area. no news MM are crooks have powder dry

2 · Reply

buymoremakemore Nov. 30 at 1:43 AM

$SGMT we are trending?

1 · Reply

doctorslopadopolis Nov. 30 at 1:38 AM

$SGMT

0 · Reply

Norny44 Nov. 29 at 2:18 PM

$SGMT Are we expecting any sort of significant updates at Tuesdays conference? I am thinking if anything new then a PR would have come beforehand unless we get a PR tomorrow ???

1 · Reply

Norny44 Nov. 26 at 2:09 PM

$SGMT Would be nice to get a PR of some sort before the conference next week!!!. Havent had anything significant here for a while??

0 · Reply

Iightning Nov. 26 at 5:21 AM

1ightning® Options Trade Alert (Actionable) | Buy $SGMT Dec 19 $8 Call | Enter: $0.29 Exit: $0.50 | Profit: 75.16% ROI | https://1ightning.com

0 · Reply

Norny44 Nov. 25 at 7:50 PM

$SGMT is today the turning point for this little cash cow?. Conference next week may or may not give some insight to things but either way this is still waaaaaaaaay too cheap!!!

1 · Reply

Market Cap	197.90M
Revenue (ttm)	0.00
Net Income (ttm)	-45.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	809,600
Avg Vol	547,088
Day's Range	N/A - N/A
Shares Out	32.52M
Stochastic %K	22%
Beta	3.32
Analysts	Strong Sell
Price Target	$28.14